

22nd November, 2017

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Fax No.:022-26598237 / 38
NSE Symbol : PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
Fax No.:022-22721919, 3121
BSE Scrip Code: 531349

Reg.: Unaudited Financial Results (Provisional) for the quarter and half year ended 30th September, 2017 - Corrigendum

Dear Sir,

This is in continuation to our letter dated 14th November, 2017 vide which we have submitted the Statement of Unaudited Financial Results (Provisional) of the Company for the quarter and half year ended 30th September, 2017.

We have now observed that inadvertently there has been a typographical error in the 'Extract of Statement of Unaudited Financial Results (Provisional) for the quarter and half year ended 30th September, 2017' submitted as above wherein the sub-headings of 2nd and 3rd Column i.e. September 30, 2016 and June 30, 2017 under the heading 'Quarter ended' were wrongly interchanged.

Please note that there is no other change in the said Unaudited Financial Results.

The said Extract of Statement is hereby replaced and is attached herewith for your records.

We request you to kindly bring the above information to the notice of your members.

Inconvenience is regretted.

Thanking you,
Yours truly,
for Panacea Biotec Ltd.


Vinod Goel
Group CFO and Head Legal
& Company Secretary



Encl. : As above

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoel@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9070

Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

(Rs. in Lakhs except per share)

Particulars	Extract of Standalone Unaudited Financial Results for the Quarter and Half year ended September 30, 2017				
	Quarter ended			Half Year ended	
	September 30, 2017	September 30, 2016	June 30, 2017	September 30, 2017	September 30, 2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
Total income from operations	15,441	16,171	10,887	26,328	29,878
Net Profit / (Loss) from ordinary activities after tax	(563)	(495)	(4,799)	(5,362)	(2,544)
Net Profit / (Loss) for the period after tax (after Extraordinary items)	(563)	(495)	(4,799)	(5,362)	(2,544)
Equity Share Capital (face value of Re.1 per share)	613	613	613	613	613
Earning per Share (before and after extraordinary items) of Re. 1 each (annualised, other than Quarter)					
Basic :	(0.92)	(0.81)	(7.84)	(8.75)	(4.15)
Diluted:	(0.92)	(0.81)	(7.84)	(8.75)	(4.15)

Notes:

- The above is an extract of the detailed format of Quarterly and Half Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Half Yearly Financial Results is available on the Stock Exchanges websites, NSE- <http://www.nseindia.com>, BSE- <http://www.bseindia.com> and is also available on the Company's website, <http://www.panaceabiotec.com>.
- The above financial results were reviewed by the Audit Committee of the Board and approved by the Board of Directors at their meetings held on November 13, 2017 and November 14, 2017 respectively. Further, the limited review of Financial Results for the Quarter and Half Year ended September 30, 2017, in terms of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, has been carried out by the statutory auditors.
- The Company has adopted Indian Accounting Standards ("IND-AS") effective April 1, 2017 (transition date being April 1, 2016). Accordingly, the financial results for the Quarter and Half Year ended September 30, 2017 have been prepared in accordance with the recognition and measurement principles laid down in the IND-AS prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. IND-AS compliant financial results, pertaining to the Quarter and Half Year ended September 30, 2016, have not been subjected to limited review or audit. However, the management has exercised necessary due diligence to ensure that the financial results and position provide a true and fair view of its affairs.
- Previous period / year amounts have been regrouped/ reclassified to make them comparable with those of current period/year.

Place: New Delhi

Date: November 14, 2017

Panacea Biotec Limited

Regd. Office : Ambala-Chandigarh Highway, Lalru- 140501, Punjab

CIN: L33117PB1984PLC022350 - Ph. No. 91-11-41679000, Fax: 91-11-41679070, Website: <http://www.panacea-biotec.com>, E-mail: corporate@panaceabiotec.com

For and on behalf of the Board

Sandeep Jain
Sandeep Jain
Joint Managing Director

[Signature]